Patritumab deruxtecan shows activity in EGFR-mutant NSCLC

Nat Rev Clin Oncol. 2023 Dec;20(12):817. doi: 10.1038/s41571-023-00822-6.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics

Substances

  • patritumab deruxtecan
  • Antibodies, Monoclonal, Humanized
  • ErbB Receptors
  • EGFR protein, human